Hypoxia and fatty liver

World Journal of Gastroenterology

Volumn 20, Issue 41, 2014, Pages 15087-15097

  Suzuki, Tomohiro ^a   Shinjo, Satoko ^a   Arai, Takatomo ^a   Kanai, Mai ^a   Goda, Nobuhito ^a  

^a WASEDA UNIVERSITY   (Japan)

Author keywords

Fatty liver disease; Hypoxia; Hypoxia inducible factor; Lipid metabolism; Obstructive sleep apnea

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2; HYPOXIA INDUCIBLE FACTOR 2ALPHA; HYPOXIA INDUCIBLE FACTOR 3ALPHA; OXYGEN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HIF3A PROTEIN, HUMAN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD FLOW; CELL CYCLE; CELL METABOLISM; CELL PROLIFERATION; DISEASE COURSE; ERYTHROPOIESIS; FATTY LIVER; GLYCOLYSIS; HUMAN; HYPOXIA; LIPID HOMEOSTASIS; LIPID METABOLISM; LIPID STORAGE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; OXYGEN SUPPLY; SLEEP DISORDERED BREATHING; VASODILATATION; ANIMAL; ANOXIA; COMPLICATION; LIVER; METABOLISM; OBESITY; PATHOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; ANOXIA; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; FATTY LIVER; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPID METABOLISM; LIVER; OBESITY; OXYGEN; RISK FACTORS; SIGNAL TRANSDUCTION; SLEEP APNEA, OBSTRUCTIVE;

EID: 84912059180     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i41.15087     Document Type: Article

References (125)

1. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 1572-1585 [PMID: 21920463 DOI: 10.1053/j.gastro.2011.09.002]
2. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011; 332: 1519-1523 [PMID: 21700865 DOI: 10.1126/science.1204265]
3. Savage DB, Semple RK. Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol 2010; 21: 329-336 [PMID: 20581678 DOI: 10.1097/MOL.0b013e32833b7782]
4. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008; 19: 371-379 [PMID: 18929493 DOI: 10.1016/j.tem.2008.08.005]
5. Crabb DW, Liangpunsakul S. Alcohol and lipid metabolism. J Gastroenterol Hepatol 2006; 21 Suppl 3: S56-S60 [PMID: 16958674 DOI: 10.1111/j.1440-1746.2006.04582.x]
6. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343-1351 [PMID: 15864352 DOI: 10.1172/JCI23621]
7. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008; 118: 829-838 [PMID: 18317565 DOI: 10.1172/JCI34275]
8. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006; 124: 35-46 [PMID: 16413480 DOI: 10.1016/j.cell.2005.12.022]
9. Raghow R, Yellaturu C, Deng X, Park EA, Elam MB. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab 2008; 19: 65-73 [PMID: 18291668 DOI: 10.1016/j.tem.2007.10.009]
10. Purohit V, Gao B, Song BJ. Molecular mechanisms of alcoholic fatty liver. Alcohol Clin Exp Res 2009; 33: 191-205 [PMID: 19032584 DOI: 10.1111/j.1530-0277.2008.00827.x]
11. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 2006; 290: G852-G858 [PMID: 16603729 DOI: 10.1152/ajpgi.00521.2005]
12. Fernández Gianotti T, Burgueño A, Gonzales Mansilla N, Pirola CJ, Sookoian S. Fatty liver is associated with transcriptional downregulation of stearoyl-CoA desaturase and impaired protein dimerization. PLoS One 2013; 8: e76912 [PMID: 24098813 DOI: 10.1371/journal.pone.0076912]
13. Dobrzyn A, Ntambi JM. Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes Rev 2005; 6: 169-174 [PMID: 15836467 DOI: 10.1111/j.1467-789X.2005.00177.x]
14. Kurikawa N, Takagi T, Wakimoto S, Uto Y, Terashima H, Kono K, Ogata T, Ohsumi J. A novel inhibitor of stearoyl- CoA desaturase-1 attenuates hepatic lipid accumulation, liver injury and inflammation in model of nonalcoholic steatohepatitis. Biol Pharm Bull 2013; 36: 259-267 [PMID: 23370355]
15. Silbernagel G, Kovarova M, Cegan A, Machann J, Schick F, Lehmann R, Häring HU, Stefan N, Schleicher E, Fritsche A, Peter A. High hepatic SCD1 activity is associated with low liver fat content in healthy subjects under a lipogenic diet. J Clin Endocrinol Metab 2012; 97: E2288-E2292 [PMID: 23015656 DOI: 10.1210/jc.2012-2152]
16. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10: 355-361 [PMID: 15057233 DOI: 10.1038/nm1025]
17. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B, Reitman ML, Gonzalez FJ. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 2003; 111: 737-747 [PMID: 12618528 DOI: 10.1172/JCI17223]
18. Zheng H, Li S, Ma L, Cheng L, Deng C, Chen Z, Xie C, Xiang M, Jiang W, Chen L. A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance. Eur J Pharmacol 2011; 659: 244-251 [PMID: 21463618 DOI: 10.1016/j.ejphar.2011.03.033]
19. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-110 [PMID: 18503774 DOI: 10.1053/j.gastro.2008.03.078]
20. Nakagami H, Kiomy Osako M, Nakagami F, Shimosato T, Minobe N, Moritani T, Shimamura M, Miyake T, Shimizu H, Takeya Y, Morishita R. Prevention and regression of nonalcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan. Int J Mol Med 2010; 26: 477-481 [PMID: 20818485]
21. Hirata T, Tomita K, Kawai T, Yokoyama H, Shimada A, Kikuchi M, Hirose H, Ebinuma H, Irie J, Ojiro K, Oikawa Y, Saito H, Itoh H, Hibi T. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY). Int J Endocrinol 2013; 2013: 587140 [PMID: 23997767 DOI: 10.1155/2013/587140]
22. Lee AH, Scapa EF, Cohen DE, Glimcher LH. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science 2008; 320: 1492-1496 [PMID: 18556558 DOI: 10.1126/science.1158042]
23. Ma L, Robinson LN, Towle HC. ChREBP∗Mlx is the principal mediator of glucose-induced gene expression in the liver. J Biol Chem 2006; 281: 28721-28730 [PMID: 16885160 DOI: 10.1074/jbc.M601576200]
24. Videla L, Bernstein J, Israel Y. Metabolic alterations produced in the liver by chronic ethanol administration. Increased oxidative capacity. Biochem J 1973; 134: 507-514 [PMID: 16742811]
25. Arteel GE, Iimuro Y, Yin M, Raleigh JA, Thurman RG. Chronic enteral ethanol treatment causes hypoxia in rat liver tissue in vivo. Hepatology 1997; 25: 920-926 [PMID: 9096598 DOI: 10.1002/hep.510250422]
26. French SW. The role of hypoxia in the pathogenesis of alcoholic liver disease. Hepatol Res 2004; 29: 69-74 [PMID: 15163427 DOI: 10.1016/j.hepres.2004.02.006]
27. Jungermann K, Kietzmann T. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology 2000; 31: 255-260 [PMID: 10655244 DOI: 10.1002/hep.510310201]
28. Mantena SK, Vaughn DP, Andringa KK, Eccleston HB, King AL, Abrams GA, Doeller JE, Kraus DW, Darley-Usmar VM, Bailey SM. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochem J 2009; 417: 183-193 [PMID: 18752470 DOI: 10.1042/BJ20080868]
29. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514 [PMID: 7539918]
30. Semenza GL. Regulation of oxygen homeostasis by hypoxiainducible factor 1. Physiology (Bethesda) 2009; 24: 97-106 [PMID: 19364912 DOI: 10.1152/physiol.00045.2008]
31. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010; 40: 294-309 [PMID: 20965423 DOI: 10.1016/j.molcel.2010.09.022]
32. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12: 9-22 [PMID: 22169972 DOI: 10.1038/nrc3183]
33. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007; 12: 108-113 [PMID: 17692803 DOI: 10.1016/j.ccr.2007.07.006]
34. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005; 2005: re12 [PMID: 16234508 DOI: 10.1126/stke.3062005re12]
35. Scortegagna M, Ding K, Oktay Y, Gaur A, Thurmond F, Yan LJ, Marck BT, Matsumoto AM, Shelton JM, Richardson JA, Bennett MJ, Garcia JA. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat Genet 2003; 35: 331-340 [PMID: 14608355 DOI: 10.1038/ng1266]
36. Makino Y, Kanopka A, Wilson WJ, Tanaka H, Poellinger L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J Biol Chem 2002; 277: 32405-32408 [PMID: 12119283 DOI: 10.1074/jbc.C200328200]
37. Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008; 30: 393-402 [PMID: 18498744 DOI: 10.1016/j.molcel.2008.04.009]
38. Aragonés J, Fraisl P, Baes M, Carmeliet P. Oxygen sensors at the crossroad of metabolism. Cell Metab 2009; 9: 11-22 [PMID: 19117543 DOI: 10.1016/j.cmet.2008.10.001]
39. Safran M, Kaelin WG. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest 2003; 111: 779-783 [PMID: 12639980 DOI: 10.1172/JCI18181]
40. Lando D, Gorman JJ, Whitelaw ML, Peet DJ. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. Eur J Biochem 2003; 270: 781-790 [PMID: 12603311]
41. Simon MC, Liu L, Barnhart BC, Young RM. Hypoxiainduced signaling in the cardiovascular system. Annu Rev Physiol 2008; 70: 51-71 [PMID: 17850210 DOI: 10.1146/annurev. physiol.70.113006.100526]
42. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393-410 [PMID: 21606941 DOI: 10.1038/nrc3064]
43. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364: 656-665 [PMID: 21323543 DOI: 10.1056/NEJMra0910283]
44. Nath B, Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology 2012; 55: 622-633 [PMID: 22120903 DOI: 10.1002/hep.25497]
45. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997; 77: 517-544 [PMID: 9114822]
46. Gorsky LD, Koop DR, Coon MJ. On the stoichiometry of the oxidase and monooxygenase reactions catalyzed by liver microsomal cytochrome P-450. Products of oxygen reduction. J Biol Chem 1984; 259: 6812-6817 [PMID: 6725272]
47. Thurman RG, Ji S, Matsumura T, Lemasters JJ. Is hypoxia involved in the mechanism of alcohol-induced liver injury? Fundam Appl Toxicol 1984; 4: 125-133 [PMID: 6724187]
48. French SW, Benson NC, Sun PS. Centrilobular liver necrosis induced by hypoxia in chronic ethanol-fed rats. Hepatology 1984; 4: 912-917 [PMID: 6479856]
49. Sato N, Kamada T, Kawano S, Hayashi N, Kishida Y, Meren H, Yoshihara H, Abe H. Effect of acute and chronic ethanol consumption on hepatic tissue oxygen tension in rats. Pharmacol Biochem Behav 1983; 18 Suppl 1: 443-447 [PMID: 6685303]
50. Tsukamoto H, Xi XP. Incomplete compensation of enhanced hepatic oxygen consumption in rats with alcoholic centrilobular liver necrosis. Hepatology 1989; 9: 302-306 [PMID: 2912830]
51. Henly DC, Berry MN. Effect of palmitate concentration on the relative contributions of the beta-oxidation pathway and citric acid cycle to total O2 consumption of isolated rat hepatocytes. Biochim Biophys Acta 1993; 1175: 269-276 [PMID: 8435443]
52. Nasrin N, Wu X, Fortier E, Feng Y, Bare' OC, Chen S, Ren X, Wu Z, Streeper RS, Bordone L. SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells. J Biol Chem 2010; 285: 31995-32002 [PMID: 20685656 DOI: 10.1074/jbc.M110.124164]
53. Kondo K, Sugioka T, Tsukada K, Aizawa M, Takizawa M, Shimizu K, Morimoto M, Suematsu M, Goda N. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. Adv Exp Med Biol 2010; 662: 77-82 [PMID: 20204774 DOI: 10.1007/978-1-4419-1241-1-10]
54. Kaelin WG. ROS: really involved in oxygen sensing. Cell Metab 2005; 1: 357-358 [PMID: 16054083 DOI: 10.1016/j.cmet.2005.05.006]
55. Klimova T, Chandel NS. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ 2008; 15: 660-666 [PMID: 18219320 DOI: 10.1038/sj.cdd.4402307]
56. Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol 2013; 58: 395-398 [PMID: 22940046 DOI: 10.1016/j.jhep.2012.08.018]
57. Wang X, Wu D, Yang L, Gan L, Cederbaum AI. Cytochrome P450 2E1 potentiates ethanol induction of hypoxia and HIF- 1α in vivo. Free Radic Biol Med 2013; 63: 175-186 [PMID: 23669278 DOI: 10.1016/j.freeradbiomed.2013.05.009]
58. Carabelli J, Burgueño AL, Rosselli MS, Gianotti TF, Lago NR, Pirola CJ, Sookoian S. High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia. J Cell Mol Med 2011; 15: 1329-1338 [PMID: 20629985 DOI: 10.1111/j.1582-4934.2010.01128.x]
59. Nishiyama Y, Goda N, Kanai M, Niwa D, Osanai K, Yamamoto Y, Senoo-Matsuda N, Johnson RS, Miura S, Kabe Y, Suematsu M. HIF-1α induction suppresses excessive lipid accumulation in alcoholic fatty liver in mice. J Hepatol 2012; 56: 441-447 [PMID: 21896344 DOI: 10.1016/j.jhep.2011.07.024]
60. Nath B, Levin I, Csak T, Petrasek J, Mueller C, Kodys K, Catalano D, Mandrekar P, Szabo G. Hepatocyte-specific hypoxia-inducible factor-1α is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice. Hepatology 2011; 53: 1526-1537 [PMID: 21520168 DOI: 10.1002/hep.24256]
61. Gordon GB, Barcza MA, Bush ME. Lipid accumulation of hypoxic tissue culture cells. Am J Pathol 1977; 88: 663-678 [PMID: 196505]
62. Whitmer JT, Idell-Wenger JA, Rovetto MJ, Neely JR. Control of fatty acid metabolism in ischemic and hypoxic hearts. J Biol Chem 1978; 253: 4305-4309 [PMID: 659417]
63. Boström P, Magnusson B, Svensson PA, Wiklund O, Borén J, Carlsson LM, Ståhlman M, Olofsson SO, Hultén LM. Hypoxia converts human macrophages into triglyceride-loaded foam cells. Arterioscler Thromb Vasc Biol 2006; 26: 1871-1876 [PMID: 16741148 DOI: 10.1161/01.ATV.0000229665.78997.0b]
64. Piguet AC, Stroka D, Zimmermann A, Dufour JF. Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN. Clin Sci (Lond) 2010; 118: 401-410 [PMID: 19832698 DOI: 10.1042/CS20090313]
65. Saarikoski ST, Rivera SP, Hankinson O. Mitogen-inducible gene 6 (MIG-6), adipophilin and tuftelin are inducible by hypoxia. FEBS Lett 2002; 530: 186-190 [PMID: 12387890]
66. Parathath S, Mick SL, Feig JE, Joaquin V, Grauer L, Habiel DM, Gassmann M, Gardner LB, Fisher EA. Hypoxia is present in murine atherosclerotic plaques and has multiple adverse effects on macrophage lipid metabolism. Circ Res 2011; 109: 1141-1152 [PMID: 21921268 DOI: 10.1161/CIRCRESAHA. 111.246363]
67. Furuta E, Pai SK, Zhan R, Bandyopadhyay S, Watabe M, Mo YY, Hirota S, Hosobe S, Tsukada T, Miura K, Kamada S, Saito K, Iiizumi M, Liu W, Ericsson J, Watabe K. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res 2008; 68: 1003-1011 [PMID: 18281474 DOI: 10.1158/0008-5472.CAN-07-2489]
68. Pinthus JH, Whelan KF, Gallino D, Lu JP, Rothschild N. Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications. Can Urol Assoc J 2011; 5: 274-282 [PMID: 21801687 DOI: 10.5489/cuaj.10196]
69. Haase VH, Glickman JN, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA 2001; 98: 1583-1588 [PMID: 11171994 DOI: 10.1073/pnas.98.4.1583]
70. Ma W, Tessarollo L, Hong SB, Baba M, Southon E, Back TC, Spence S, Lobe CG, Sharma N, Maher GW, Pack S, Vortmeyer AO, Guo C, Zbar B, Schmidt LS. Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res 2003; 63: 5320-5328 [PMID: 14500363]
71. Rankin EB, Rha J, Selak MA, Unger TL, Keith B, Liu Q, Haase VH. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol 2009; 29: 4527-4538 [PMID: 19528226 DOI: 10.1128/MCB.00200-09]
72. Kucejova B, Sunny NE, Nguyen AD, Hallac R, Fu X, Peña- Llopis S, Mason RP, Deberardinis RJ, Xie XJ, Debose-Boyd R, Kodibagkar VD, Burgess SC, Brugarolas J. Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death. Oncogene 2011; 30: 2147-2160 [PMID: 21217781 DOI: 10.1038/onc.2010.587]
73. Qu A, Taylor M, Xue X, Matsubara T, Metzger D, Chambon P, Gonzalez FJ, Shah YM. Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology 2011; 54: 472-483 [PMID: 21538443 DOI: 10.1002/hep.24400]
74. Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol 2009; 29: 5729-5741 [PMID: 19720742 DOI: 10.1128/MCB.00331-09]
75. Kim WY, Safran M, Buckley MR, Ebert BL, Glickman J, Bosenberg M, Regan M, Kaelin WG. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J 2006; 25: 4650-4662 [PMID: 16977322 DOI: 10.1038/sj.emboj.7601300]
76. Yun Z, Maecker HL, Johnson RS, Giaccia AJ. Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell 2002; 2: 331-341 [PMID: 11879638]
77. Choi SM, Cho HJ, Cho H, Kim KH, Kim JB, Park H. Stra13/DEC1 and DEC2 inhibit sterol regulatory element binding protein-1c in a hypoxia-inducible factor-dependent mechanism. Nucleic Acids Res 2008; 36: 6372-6385 [PMID: 18838394 DOI: 10.1093/nar/gkn620]
78. Wang XL, Suzuki R, Lee K, Tran T, Gunton JE, Saha AK, Patti ME, Goldfine A, Ruderman NB, Gonzalez FJ, Kahn CR. Ablation of ARNT/HIF1beta in liver alters gluconeogenesis, lipogenic gene expression, and serum ketones. Cell Metab 2009; 9: 428-439 [PMID: 19416713 DOI: 10.1016/j.cmet.2009.04.001]
79. Bonello S, Zähringer C, BelAiba RS, Djordjevic T, Hess J, Michiels C, Kietzmann T, Görlach A. Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol 2007; 27: 755-761 [PMID: 17272744 DOI: 10.1161/01.ATV.0000258979.92828.bc]
80. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008; 453: 807-811 [PMID: 18432192 DOI: 10.1038/nature06905]
81. Kuhlicke J, Frick JS, Morote-Garcia JC, Rosenberger P, Eltzschig HK. Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia. PLoS One 2007; 2: e1364 [PMID: 18159247 DOI: 10.1371/journal.pone.0001364]
82. Kim SY, Choi YJ, Joung SM, Lee BH, Jung YS, Lee JY. Hypoxic stress up-regulates the expression of Toll-like receptor 4 in macrophages via hypoxia-inducible factor. Immunology 2010; 129: 516-524 [PMID: 20002786 DOI: 10.1111/j.1365-2567.2009.03203.x]
83. Huang W, Metlakunta A, Dedousis N, Zhang P, Sipula I, Dube JJ, Scott DK, O'Doherty RM. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 2010; 59: 347-357 [PMID: 19934001 DOI: 10.2337/db09-0016]
84. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, Olefsky JM, Brenner DA, Seki E. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice. Gastroenterology 2010; 139: 323-324.e7 [PMID: 20347818 DOI: 10.1053/j.gastro.2010.03.052]
85. Stienstra R, Saudale F, Duval C, Keshtkar S, Groener JE, van Rooijen N, Staels B, Kersten S, Müller M. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 2010; 51: 511-522 [PMID: 20054868 DOI: 10.1002/hep.23337]
86. Kersten S. Regulation of nutrient metabolism and inflammation. Results Probl Cell Differ 2010; 52: 13-25 [PMID: 20865368 DOI: 10.1007/978-3-642-14426-4-2]
87. Rosmorduc O, Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010; 30: 258-270 [PMID: 20665378 DOI: 10.1055/s-0030-1255355]
88. Cannito S, Paternostro C, Busletta C, Bocca C, Colombatto S, Miglietta A, Novo E, Parola M. Hypoxia, hypoxia-inducible factors and fibrogenesis in chronic liver diseases. Histol Histopathol 2014; 29: 33-44 [PMID: 23996844]
89. Paternostro C, David E, Novo E, Parola M. Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases. World J Gastroenterol 2010; 16: 281-288 [PMID: 20082471]
90. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, Housset C, Rosmorduc O. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002; 35: 1010-1021 [PMID: 11981751 DOI: 10.1053/jhep.2002.32524]
91. Novo E, Cannito S, Zamara E, Valfrè di Bonzo L, Caligiuri A, Cravanzola C, Compagnone A, Colombatto S, Marra F, Pinzani M, Parola M. Proangiogenic cytokines as hypoxiadependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 2007; 170: 1942-1953 [PMID: 17525262]
92. Novo E, Povero D, Busletta C, Paternostro C, di Bonzo LV, Cannito S, Compagnone A, Bandino A, Marra F, Colombatto S, David E, Pinzani M, Parola M. The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells. J Pathol 2012; 226: 588-597 [PMID: 21959987 DOI: 10.1002/path.3005]
93. Moon JO, Welch TP, Gonzalez FJ, Copple BL. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol 2009; 296: G582-G592 [PMID: 19136383 DOI: 10.1152/ajpgi.90368.2008]
94. Copple BL, Bustamante JJ, Welch TP, Kim ND, Moon JO. Hypoxia-inducible factor-dependent production of profibrotic mediators by hypoxic hepatocytes. Liver Int 2009; 29: 1010-1021 [PMID: 19302442 DOI: 10.1111/j.1478-3231.2009.02015.x]
95. Kuwabara K, Ogawa S, Matsumoto M, Koga S, Clauss M, Pinsky DJ, Lyn P, Leavy J, Witte L, Joseph-Silverstein J. Hypoxia- mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 1995; 92: 4606-4610 [PMID: 7538678]
96. Copple BL, Bai S, Burgoon LD, Moon JO. Hypoxia-inducible factor-1α regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int 2011; 31: 230-244 [PMID: 20880076 DOI: 10.1111/j.1478-3231.2010.02347.x]
97. Copple BL, Kaska S, Wentling C. Hypoxia-inducible factor activation in myeloid cells contributes to the development of liver fibrosis in cholestatic mice. J Pharmacol Exp Ther 2012; 341: 307-316 [PMID: 22271822 DOI: 10.1124/jpet.111.189340]
98. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, Iredale JP. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56-65 [PMID: 15630444 DOI: 10.1172/JCI22675]
99. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010; 30: 245-257 [PMID: 20665377 DOI: 10.1055/s-0030-1255354]
100. Takeda N, O'Dea EL, Doedens A, Kim JW, Weidemann A, Stockmann C, Asagiri M, Simon MC, Hoffmann A, Johnson RS. Differential activation and antagonistic function of HIF- {alpha} isoforms in macrophages are essential for NO homeostasis. Genes Dev 2010; 24: 491-501 [PMID: 20194441 DOI: 10.1101/gad.1881410]
101. Noordeen NA, Khera TK, Sun G, Longbottom ER, Pullen TJ, da Silva Xavier G, Rutter GA, Leclerc I. Carbohydrateresponsive element-binding protein (ChREBP) is a negative regulator of ARNT/HIF-1beta gene expression in pancreatic islet beta-cells. Diabetes 2010; 59: 153-160 [PMID: 19833882 DOI: 10.2337/db08-0868]
102. Gastaut H, Tassinari CA, Duron B. Polygraphic study of the episodic diurnal and nocturnal (hypnic and respiratory) manifestations of the Pickwick syndrome. Brain Res 1966; 1: 167-186 [PMID: 5923125]
103. Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002; 165: 670-676 [PMID: 11874812 DOI: 10.1164/ajrccm.165.5.2103001]
104. Tanné F, Gagnadoux F, Chazouillères O, Fleury B, Wendum D, Lasnier E, Lebeau B, Poupon R, Serfaty L. Chronic liver injury during obstructive sleep apnea. Hepatology 2005; 41: 1290-1296 [PMID: 15915459 DOI: 10.1002/hep.20725]
105. Kallwitz ER, Herdegen J, Madura J, Jakate S, Cotler SJ. Liver enzymes and histology in obese patients with obstructive sleep apnea. J Clin Gastroenterol 2007; 41: 918-921 [PMID: 18090161 DOI: 10.1097/01.mcg.0000225692.62121.55]
106. Jouët P, Sabaté JM, Maillard D, Msika S, Mechler C, Ledoux S, Harnois F, Coffin B. Relationship between obstructive sleep apnea and liver abnormalities in morbidly obese patients: a prospective study. Obes Surg 2007; 17: 478-485 [PMID: 17608260 DOI: 10.1007/s11695-007-9085-3]
107. Polotsky VY, Patil SP, Savransky V, Laffan A, Fonti S, Frame LA, Steele KE, Schweizter MA, Clark JM, Torbenson MS, Schwartz AR. Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med 2009; 179: 228-234 [PMID: 18990675 DOI: 10.1164/rccm.200804-608OC]
108. Kheirandish-Gozal L, Sans Capdevila O, Kheirandish E, Gozal D. Elevated serum aminotransferase levels in children at risk for obstructive sleep apnea. Chest 2008; 133: 92-99 [PMID: 18187742 DOI: 10.1378/chest.07-0773]
109. Aron-Wisnewsky J, Minville C, Tordjman J, Lévy P, Bouillot JL, Basdevant A, Bedossa P, Clément K, Pépin JL. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol 2012; 56: 225-233 [PMID: 21703181 DOI: 10.1016/j.jhep.2011.04.022]
110. Sookoian S, Pirola CJ. Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. Obes Surg 2013; 23: 1815-1825 [PMID: 23740153 DOI: 10.1007/s11695-013-0981-4]
111. Fletcher EC, Lesske J, Qian W, Miller CC, Unger T. Repetitive, episodic hypoxia causes diurnal elevation of blood pressure in rats. Hypertension 1992; 19: 555-561 [PMID: 1592450]
112. Li J, Thorne LN, Punjabi NM, Sun CK, Schwartz AR, Smith PL, Marino RL, Rodriguez A, Hubbard WC, O'Donnell CP, Polotsky VY. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 2005; 97: 698-706 [PMID: 16123334 DOI: 10.1161/01.RES.0000183879.60089.a9]
113. Savransky V, Nanayakkara A, Vivero A, Li J, Bevans S, Smith PL, Torbenson MS, Polotsky VY. Chronic intermittent hypoxia predisposes to liver injury. Hepatology 2007; 45: 1007-1013 [PMID: 17393512 DOI: 10.1002/hep.21593]
114. Li J, Grigoryev DN, Ye SQ, Thorne L, Schwartz AR, Smith PL, O'Donnell CP, Polotsky VY. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J Appl Physiol (1985) 2005; 99: 1643-1648 [PMID: 16037401 DOI: 10.1152/japplphysiol.00522.2005]
115. Drager LF, Li J, Reinke C, Bevans-Fonti S, Jun JC, Polotsky VY. Intermittent hypoxia exacerbates metabolic effects of diet- induced obesity. Obesity (Silver Spring) 2011; 19: 2167-2174 [PMID: 21799478 DOI: 10.1038/oby.2011.240]
116. Yuan G, Nanduri J, Khan S, Semenza GL, Prabhakar NR. Induction of HIF-1alpha expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J Cell Physiol 2008; 217: 674-685 [PMID: 18651560 DOI: 10.1002/jcp.21537]
117. Yuan G, Nanduri J, Bhasker CR, Semenza GL, Prabhakar NR. Ca2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem 2005; 280: 4321-4328 [PMID: 15569687 DOI: 10.1074/jbc.M407706200]
118. Malec V, Gottschald OR, Li S, Rose F, Seeger W, Hänze J. HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. Free Radic Biol Med 2010; 48: 1626-1635 [PMID: 20347035 DOI: 10.1016/j.freeradbiomed.20 10.03.008]
119. Nanduri J, Wang N, Yuan G, Khan SA, Souvannakitti D, Peng YJ, Kumar GK, Garcia JA, Prabhakar NR. Intermittent hypoxia degrades HIF-2alpha via calpains resulting in oxidative stress: implications for recurrent apnea-induced morbidities. Proc Natl Acad Sci USA 2009; 106: 1199-1204 [PMID: 19147445 DOI: 10.1073/pnas.0811018106]
120. Nanduri J, Vaddi DR, Khan SA, Wang N, Makerenko V, Prabhakar NR. Xanthine oxidase mediates hypoxia-inducible factor-2α degradation by intermittent hypoxia. PLoS One 2013; 8: e75838 [PMID: 24124516 DOI: 10.1371/journal. pone.0075838]
121. Li J, Bosch-Marce M, Nanayakkara A, Savransky V, Fried SK, Semenza GL, Polotsky VY. Altered metabolic responses to intermittent hypoxia in mice with partial deficiency of hypoxia-inducible factor-1alpha. Physiol Genomics 2006; 25: 450-457 [PMID: 16507783 DOI: 10.1152/physiolgenomics. 00293.2005]
122. Peng YJ, Yuan G, Ramakrishnan D, Sharma SD, Bosch-Marce M, Kumar GK, Semenza GL, Prabhakar NR. Heterozygous HIF-1alpha deficiency impairs carotid body-mediated systemic responses and reactive oxygen species generation in mice exposed to intermittent hypoxia. J Physiol 2006; 577: 705-716 [PMID: 16973705 DOI: 10.1113/jphysiol.2006.114033]
123. Jiang C, Kim JH, Li F, Qu A, Gavrilova O, Shah YM, Gonzalez FJ. Hypoxia-inducible factor 1α regulates a SOCS3- STAT3-adiponectin signal transduction pathway in adipocytes. J Biol Chem 2013; 288: 3844-3857 [PMID: 23255598 DOI: 10.1074/jbc.M112.426338]
124. Jiang C, Qu A, Matsubara T, Chanturiya T, Jou W, Gavrilova O, Shah YM, Gonzalez FJ. Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice. Diabetes 2011; 60: 2484-2495 [PMID: 21873554 DOI: 10.2337/db11-0174]
125. Sun K, Halberg N, Khan M, Magalang UJ, Scherer PE. Selective inhibition of hypoxia-inducible factor 1α ameliorates adipose tissue dysfunction. Mol Cell Biol 2013; 33: 904-917 [PMID: 23249949 DOI: 10.1128/MCB.00951-12]